Company: ZVRA
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001434647-25-000011
Chunk: 133

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 8
Chunk 133
---
30, 2025, and December 31, 2024.Accounts and Other ReceivablesAccounts and other receivables consist of receivables from product sales of MIPLYFFA and OLPRUVA, reimbursements received under the French AC, royalties generated under the AZSTARYS License Agreement, and other receivables due to the Company. Receivables under the AZSTARYS License Agreement are recorded for amounts due to the Company related to reimbursable third-party costs as well as milestones and royalties on product sales. Receivables are recorded for commercial sales of MIPLYFFA and OLPRUVA to a single specialty pharmacy and product sales under the French AC. The Company provides reserves against receivables for estimated losses that may result from a customer's inability to pay. Receivables are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions, specific circumstances and the Company’s own historical collection experience. Amounts determined to be uncollectible are charged or written-off against the reserve. 

19

Accounts and other receivables consist of the following (in thousands): September 30,2025December 31,2024Commercial accounts receivable$8,770 $4,010 Receivables related to product reimbursements6,056 5,380 Royalties accounts receivable1,200 786 Other receivables815 333 Total receivables$16,841 $10,509 

 As of September 30, 2025, and December 31, 2024, no reserve or allowance for doubtful accounts had been established. 

G.    Stock and Warrants

Authorized, Issued, and Outstanding Common SharesAs of September 30, 2025, and December 31, 2024, the Company had authorized shares of common stock of 250,000,000 shares. Of the authorized shares, 57,793,414 and 55,246,401 shares of common stock were issued as of September 30, 2025, and December 31, 2024, respectively, and 56,217,722 and 53,670,709 shares of common stock were outstanding as of September 30, 2025, and December 31, 2024, respectively.As of September 30, 2025, and December 31, 2024, the Company had reserved authorized shares